ACADIA

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

September 2, 2020

SAN DIEGO--(BUSINESS WIRE)--Sep. 2, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:

Citi 15th Annual BioPharma Virtual Conference
Date: Wednesday, September 9, 2020
Panel: *Emerging Therapies for Psychiatric Disorders* at 1:30 p.m. Eastern Time

Morgan Stanley 18th Annual Global Healthcare Conference
Date: Monday, September 14, 2020
Fireside chat presentation: 3:45 p.m. Eastern Time

Cantor Virtual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Fireside chat presentation: 11:20 a.m. Eastern Time

These conferences will all be held virtually. Live webcasts of the panel and presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005382/en/

Media Contact:
ACADIA Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com

Investor Contact:
ACADIA Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Source: ACADIA Pharmaceuticals Inc.